29 September 2016
Operations Update - Delivery on Multiple Revenue Streams Imminent
• Set for first major product delivery and revenues under Californian distribution deal, with material discussions advanced on additional distribution deals across North America and Europe for its Anti-Aging product range
• Production of the Company’s first Slovenian API GMP grade cannabidiol (CBD) nearing completion, with first Active Pharmaceutical Ingredient (API) grade CBD production scheduled for Q2 2017
• Substantial progress of MGC Derma division towards launch of dermatologically tested products for the relief of several skin conditions, including Acne and Psoriasis
• Acquisition of Czech-based medical cannabis company, PANAX Pharma s.r.o (Panax) remains on track towards completion in Q4 2016
• Company to apply for an Australian Medical Cannabis licence during Q4 2016, following recent legislative changes in Australia and pursuant to Office for Drug Control process
MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”), is pleased to provide an update to shareholders on recent material progress across a number of its core business units and future revenue streams.
Why management deserve to be paid so highly
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.58M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 30.0¢ | $2.567K | 8.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 47481 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 8026 | 2 |
View Market Depth
| Last trade - 15.53pm 21/06/2024 (20 minute delay) ? |
| RGT (ASX) Chart |